TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder
Brief Summary: The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS SR versus placebo in subjects with Major Depressive Disorder. Additional objectives include testing both general and functional quality-of-life outcomes and satisfaction with therapy reported by the subject.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Low impact exercise | Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low impact exercise; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712, Drug: ADT | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: ADT | Intervention Type: DRUG; Name: OPC-34712; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: ADT; Assigned to Arm(s): 1, 2
C: Intervention Type: DRUG; Name: desvenlafaxine 50 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: desvenlafaxine 100 mg; Assigned to Arm(s): N/A
D: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-Term, Open-Label, Safety Extension Study of the Combination of Fenofibric Acid and Statin Therapy for Subjects With Mixed Dyslipidemia
Brief Summary: The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335 and rosuvastatin calcium | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335 and atorvastatin calcium | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335 and simvastatin | Intervention Type: DRUG; Name: ABT-335 and rosuvastatin calcium; Assigned to Arm(s): A | Intervention Type: DRUG; Name: ABT-335 and atorvastatin calcium; Assigned to Arm(s): B | Intervention Type: DRUG; Name: ABT-335 and simvastatin; Assigned to Arm(s): C
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Simvastatin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Simvastatin | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: ABT-335, Drug: Placebo | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Arm Label: E; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Arm Label: F; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: ABT-335; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): A, B, D, E, F | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): C, D, E, F
C: Intervention Type: DRUG; Name: Rosuvastatin (Crestor); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of ABT-335 and Simvastatin Combination Therapy to ABT-335 and Simvastatin Monotherapy in Subjects With Mixed Dyslipidemia
Brief Summary: The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + simvastatin combination therapy with ABT-335 and simvastatin monotherapy in subjects with multiple abnormal lipid levels in the blood.


Options:
A: Arm Label: ABT-335 and Rosuvastatin Calcium; Type: EXPERIMENTAL; Interventions: Drug: ABT-335 and rosuvastatin calcium | Arm Label: ABT-335; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335 | Arm Label: Rosuvastatin Calcium; Type: ACTIVE_COMPARATOR; Interventions: Drug: rosuvastatin calcium | Intervention Type: DRUG; Name: ABT-335 and rosuvastatin calcium; Assigned to Arm(s): ABT-335 and Rosuvastatin Calcium | Intervention Type: DRUG; Name: ABT-335; Assigned to Arm(s): ABT-335 | Intervention Type: DRUG; Name: rosuvastatin calcium; Assigned to Arm(s): Rosuvastatin Calcium
B: Intervention Type: DRUG; Name: MK0653A, ezetimibe (+) simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: Rosuvastatin; Assigned to Arm(s): N/A
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Atorvastatin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Atorvastatin | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: ABT-335, Drug: Placebo | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: E; Type: PLACEBO_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: F; Type: PLACEBO_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Intervention Type: DRUG; Name: ABT-335; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): A, B, D, E, F | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): C, D, E, F
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Simvastatin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Simvastatin | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: ABT-335, Drug: Placebo | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Arm Label: E; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Arm Label: F; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: ABT-335; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): A, B, D, E, F | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): C, D, E, F

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Atorvastatin Calcium Combination Therapy to Fenofibric Acid and Atorvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia
Brief Summary: The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + atorvastatin combination therapy with ABT-335 and atorvastatin monotherapy in subjects with multiple abnormal lipid levels in the blood.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Atorvastatin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Atorvastatin | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: ABT-335, Drug: Placebo | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: E; Type: PLACEBO_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: F; Type: PLACEBO_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Intervention Type: DRUG; Name: ABT-335; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): A, B, D, E, F | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): C, D, E, F
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Rosuvastatin Calcium | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Rosuvastatin Calcium | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: ABT-335, Drug: Placebo | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin Calcium, Drug: Placebo | Arm Label: E; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin Calcium, Drug: Placebo | Arm Label: F; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin Calcium, Drug: Placebo | Intervention Type: DRUG; Name: ABT-335; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Rosuvastatin Calcium; Assigned to Arm(s): A, B, D, E, F | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): C, D, E, F
C: Intervention Type: DRUG; Name: MK0653A, ezetimibe (+) simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: Rosuvastatin; Assigned to Arm(s): N/A
D: Arm Label: A - ABT-143 capsules 5/135 mg; Type: EXPERIMENTAL; Interventions: Drug: ABT-143 | Arm Label: B - ABT-143 capsules 10/135 mg; Type: EXPERIMENTAL; Interventions: Drug: ABT-143 | Arm Label: C - ABT-143 capsules 20/135 mg; Type: EXPERIMENTAL; Interventions: Drug: ABT-143 | Arm Label: D - Simvastatin capsules 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Intervention Type: DRUG; Name: ABT-143; Assigned to Arm(s): A - ABT-143 capsules 5/135 mg, B - ABT-143 capsules 10/135 mg, C - ABT-143 capsules 20/135 mg | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): D - Simvastatin capsules 40 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Rosuvastatin Calcium Combination Therapy to Fenofibric Acid and Rosuvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia
Brief Summary: The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + rosuvastatin calcium combination therapy with ABT-335 and rosuvastatin calcium monotherapy in subjects with multiple abnormal lipid levels in the blood.


Options:
A: Arm Label: rosuva 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: rosuva 10; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: rosuva 20; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: rosuva ol; Type: OTHER; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): rosuva 10, rosuva 20, rosuva 5, rosuva ol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: ABT-335 plus rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: ABT-335 plus rosuvastatin | Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: ABT-335 plus rosuvastatin; Assigned to Arm(s): ABT-335 plus rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
C: Arm Label: ABT-335 and Rosuvastatin Calcium; Type: EXPERIMENTAL; Interventions: Drug: ABT-335 and rosuvastatin calcium | Arm Label: ABT-335; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335 | Arm Label: Rosuvastatin Calcium; Type: ACTIVE_COMPARATOR; Interventions: Drug: rosuvastatin calcium | Intervention Type: DRUG; Name: ABT-335 and rosuvastatin calcium; Assigned to Arm(s): ABT-335 and Rosuvastatin Calcium | Intervention Type: DRUG; Name: ABT-335; Assigned to Arm(s): ABT-335 | Intervention Type: DRUG; Name: rosuvastatin calcium; Assigned to Arm(s): Rosuvastatin Calcium
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Rosuvastatin Calcium | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABT-335, Drug: Rosuvastatin Calcium | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: ABT-335, Drug: Placebo | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin Calcium, Drug: Placebo | Arm Label: E; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin Calcium, Drug: Placebo | Arm Label: F; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin Calcium, Drug: Placebo | Intervention Type: DRUG; Name: ABT-335; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Rosuvastatin Calcium; Assigned to Arm(s): A, B, D, E, F | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): C, D, E, F

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double Blind Placebo Controlled Pilot Trial of Memantine for Cognitive Impairment in Multiple Sclerosis
Brief Summary: This study is designed to determine whether memantine is an effective treatment for memory and cognitive problems associated with multiple sclerosis when compared to placebo.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Memantine ER; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine ER | Intervention Type: DRUG; Name: memantine ER; Assigned to Arm(s): Memantine ER | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol, Drug: Memantine | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4
C: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Donepezil | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Donepezil; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind Study of the Clinical Outcomes, Safety and Tolerability of Multiple Doses of Pantoprazole Sodium Enteric-Coated Spheroids in Children Ages 1 to 5 With Endoscopically Proven Symptomatic Gastroesophageal Reflux Disease (GERD)
Brief Summary: To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.


Options:
A: Intervention Type: DRUG; Name: pantoprazole for approximately 9 weeks.; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Intervention Type: DRUG; Name: pantoprazole sodium enteric-coated spheroid; Assigned to Arm(s): 1, 2, 3
C: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
D: Arm Label: Lansoprazole QD; Type: EXPERIMENTAL; Interventions: Drug: Lansoprazole microgranules suspension | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lansoprazole microgranules suspension; Assigned to Arm(s): Lansoprazole QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind Study of the Clinical Outcomes, Safety and Tolerability of Multiple Doses of Pantoprazole Sodium Enteric-Coated Spheroids in Children Ages 1 to 5 With Endoscopically Proven Symptomatic Gastroesophageal Reflux Disease (GERD)
Brief Summary: To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.


Options:
A: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
B: Arm Label: Oral omeprazole; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Rectal omeprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omeprazole rectally 1mg/kg | Intervention Type: DRUG; Name: Omeprazole rectally 1mg/kg; Assigned to Arm(s): Rectal omeprazole
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid | Intervention Type: DRUG; Name: pantoprazole sodium enteric-coated spheroid; Assigned to Arm(s): 1, 2, 3
D: Arm Label: Dexlansoprazole MR 30 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Arm Label: Dexlansoprazole MR 60 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 30 mg QD | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 60 mg QD

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment With Aripiprazole in Patients With Schizophrenia.
Brief Summary: The purpose of this study is to evaluate the effect on patient weight of adjunctive therapy of aripiprazole with clozapine versus clozapine monotherapy, in schizophrenic patients who are not optimally controlled on clozapine.


Options:
A: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
B: Arm Label: Aripiprazole depot 300 or 400 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 300 or 400 mg, Drug: Placebo tablets | Arm Label: Aripiprazole 10-30 mg orally; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 10-30 mg orally, Drug: Placebo depot | Arm Label: Aripiprazole depot 25 or 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 25 or 50 mg, Drug: Placebo tablets | Intervention Type: DRUG; Name: Aripiprazole depot 300 or 400 mg; Assigned to Arm(s): Aripiprazole depot 300 or 400 mg | Intervention Type: DRUG; Name: Aripiprazole 10-30 mg orally; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Aripiprazole depot 25 or 50 mg; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Placebo tablets; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg, Aripiprazole depot 300 or 400 mg
C: Arm Label: A - 10 mg loxapine q 4 h x 3 (30 mg total); Type: EXPERIMENTAL; Interventions: Drug: A - 10 mg loxapine q 4 h x 3 (30 mg total) | Arm Label: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total); Type: EXPERIMENTAL; Interventions: Drug: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total) | Arm Label: C - 5 mg loxapine q 4 h x 3 (15 mg total); Type: EXPERIMENTAL; Interventions: Drug: C - 5 mg loxapine q 4 h x 3 (15 mg total) | Arm Label: D - inhaled placebo q 4 h x 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: D - inhaled placebo q 4 h x 3 | Intervention Type: DRUG; Name: A - 10 mg loxapine q 4 h x 3 (30 mg total); Assigned to Arm(s): A - 10 mg loxapine q 4 h x 3 (30 mg total) | Intervention Type: DRUG; Name: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total); Assigned to Arm(s): B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total) | Intervention Type: DRUG; Name: C - 5 mg loxapine q 4 h x 3 (15 mg total); Assigned to Arm(s): C - 5 mg loxapine q 4 h x 3 (15 mg total) | Intervention Type: DRUG; Name: D - inhaled placebo q 4 h x 3; Assigned to Arm(s): D - inhaled placebo q 4 h x 3
D: Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment With Aripiprazole in Patients With Schizophrenia.
Brief Summary: The purpose of this study is to evaluate the effect on patient weight of adjunctive therapy of aripiprazole with clozapine versus clozapine monotherapy, in schizophrenic patients who are not optimally controlled on clozapine.


Options:
A: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
B: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment With Aripiprazole in Patients With Schizophrenia.
Brief Summary: The purpose of this study is to evaluate the effect on patient weight of adjunctive therapy of aripiprazole with clozapine versus clozapine monotherapy, in schizophrenic patients who are not optimally controlled on clozapine.


Options:
A: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
B: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Melatonin; Type: EXPERIMENTAL; Interventions: Drug: Melatonin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Melatonin; Assigned to Arm(s): Melatonin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: lifestyle intervention; Assigned to Arm(s): N/A

Answer: A